Genfleet Therapeutics

Biomarkers

• KRAS G12D5

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

VS-7375 5GFH276 4cetuximab 3tislelizumab 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

• 2027-04 GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer Phase 2 · KRAS G12D
• 2027-07 A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation Phase 1/2 · KRAS G12D
• 2027-09 A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors Phase 1/2 · KRAS G12C, KRAS G12D

Trials

8 of 10 trials shown

1. A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation

   Recruiting Phase 3 Genfleet Therapeutics Started 2026Primary completion 2030-06 NCT07668752

   VS-7375docetaxel

   …e to undergo tumor biopsy to obtain tissue samples for central laboratory confirmation of KRAS G12D mutation.

   KRAS G12DKRAS G12D Mutation, NSCLC (Non-small Cell Lung Cancer)

2. This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.

   Not yet recruiting Phase 1/2 Genfleet Therapeutics Started 2026Primary completion 2027-12 NCT07846358

   GFH276tislelizumabpemetrexedcisplatincarboplatin

   Confirmed RAS mutation or KRAS amplification；tumor cell PD L1 test report available

   KRAS G12CKRAS G12DRAS Mutation, Non-small Cell Lung Cancer (NSCLC)

3. A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

   Recruiting Phase 1/2 Genfleet Therapeutics Started 2026Primary completion 2027-11 NCT07678593

   GFH276cetuximabnab-paclitaxelgemcitabinefluorouracilleucovorinirinotecanoxaliplatin

   …cally or cytologically confirmed locally advanced or metastatic solid tumor and PDAC with RAS mutation or KRAS amplification

   KRAS G12CKRAS G12DAdvanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma, RAS Mutation

4. A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation

   Recruiting Phase 2 Genfleet Therapeutics Started 2026Primary completion 2028-08 NCT07784374

   VS-7375GFH276GFS202A

   …reviously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation

   KRAS G12DPancreatic Cancer

5. GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer

   Not yet recruiting Phase 2 Genfleet Therapeutics Started 2026Primary completion 2027-04 NCT07554859

   VS-7375cetuximabpemetrexed

   Have a written report confirming KRAS G12D mutation positive.

   KRAS G12DNSCLC (Advanced Non-small Cell Lung Cancer)

6. A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors

   Not yet recruiting Phase 1/2 Genfleet Therapeutics Started 2025Primary completion 2027-09 NCT07198321

   GFH276

   … Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors

   KRAS G12CKRAS G12DCancer, PDAC, CRC (Colorectal Cancer), NSCLC

7. A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation

   Recruiting Phase 1/2 Genfleet Therapeutics Started 2025Primary completion 2027-07 NCT07259590

   VS-7375cetuximabpaclitaxelgemcitabine

   …or cytologically confirmed locally advanced unresectable or metastatic solid tumors, with KRAS G12D mutation.

   KRAS G12DAdvanced Solid Tumors Cancer, PDAC, CRC (Colorectal Cancer)

8. A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

   Recruiting Phase 1/2 Genfleet Therapeutics Started 2024Primary completion 2028-07 NCT06500676

   VS-7375

   …h histologically or cytologically confirmed advanced or metastatic solid tumors harboring KRAS G12D mutation.

   KRAS G12DKRAS G12D Mutations, Advanced Solid Tumors

No trials match these filters.